Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Articles about Puma Biotechnology
Puma Biotech to pay PPD founder $22M in defamation suit from proxy fight | Fierce Pharma
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Biotechnology
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology
Mirati Therapeutics Inc - Sponsored Research: Mirati Therapeutics, Inc; Boehringer-Ingelheim; Eli Lilly and Company; Takeda Oncology; Puma Biotechnology; Astellas Pharmaceuticals; AstraZeneca; Daiichi Sankyo; Revolution Medicines Consulting Fees ...
PUMA Induction by FoxO3a Mediates the Anticancer Activities of the Broad-Range Kinase Inhibitor UCN-01
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio - TheStreet
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
RETRACTED ARTICLE: Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway | Cancer Gene Therapy
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotechnology, Knight Therapeutics sign license deal to commercialize NERLYNX in Canada - Pharmaceutical Business review
Puma Biotechnology Alisertib , an Aurora Kinase A Inhibitor
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Cana
Find a Job | Puma Biotechnology, Inc.
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (nerati
Puma pounces on failed Takeda drug, snapping up cancer prospect
Puma Biotechnology Reports Third Quarter 2021 Financial Results | Business Wire
